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Background: Health state utility values (HSUVs) are important in the assessment of the cost effectiveness of new
interventions. In the case of visual conditions, models generally tend have tended to be built around a set of health
states defined by visual acuity (VA). The aim of this review was to assess the impact of VA on HSUVs in patients
with diabetic retinopathy, diabetic macular oedema or age-related macular degeneration.
Methods: A systematic literature search was undertaken in major bibliographic databases to identify articles
reporting on the relationship between HSUVs and vision. Data were extracted for population characteristics, visual
levels and estimated utilities. Evidence from reported statistical models, where available, was considered in the
evaluation of vision in the better-seeing eye and the worse-seeing eye. Due to the heterogeneity of included studies,
a narrative synthesis was undertaken.
Results: Of the 17 relevant studies, 9 studies had data that could be used in the analysis of the impact of vision on
HSUVs. Visual loss was associated with a marked impact on health utilities. However, the relationship was not
comparable between conditions or by measure of HSUVs. Key results included the finding that overall, self-rated
time-trade off estimates were more likely to discriminate between different VA levels than EQ-5D values. Additionally,
a stronger correlation was observed between HSUVs and better-seeing eye VA compared to worse-seeing eye VA.
Conclusions: Visual acuity has a significant impact on HSUVs. Nevertheless, care must be taken in the interpretation
and use of estimates in cost-effectiveness models due to differences in measures and population diversity.
Keywords: Health utility, Visual acuity, Diabetic retinopathy, Age-related macular degenerationBackground
Health state utility values (HSUVs) are key parameters
in the assessment of the cost effectiveness of new inter-
ventions [1]. In economic evaluation, the benefits of
healthcare interventions have been commonly measured
in terms of quality-adjusted life years (QALYs) where
benefits are summarised into a single measure which
combines length of life with health-related quality of life
(HRQoL) [2]. This is achieved by assigning a value to
every health state on a scale where 1 represents (usually)* Correspondence: e.poku@sheffield.ac.uk
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reproduction in any medium, provided the orfull health and 0 for states as bad as being dead. Nega-
tive values indicate states worse than death. There are a
number of possible sources of values: patients, those at
risk of developing the condition, members of the public
(with or without a similar profile to the typical patient)
or clinical staff.
There are three broad approaches to deriving HSUVs
[3]. Firstly, preferences may be elicited using specially
constructed vignettes or scenarios which describe a par-
ticular health state (such as a visual acuity category)
using one of the standard health state valuation tech-
niques such as visual analogue scaling (VAS), standard
gamble (SG) or time trade-off (TTO). Secondly, a health
state may be described using an existing questionnaired. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a set of values have been obtained from the general popu-
lation sample. Such measures includes generic preference-
based measures such as the EQ-5D, [4] SF-6D, [5] or the
HUI3 [6] and condition specific preference-based mea-
sures [7] like AQL-5D for asthma [8], EORTC-8D for
multiple myeloma cancer [9] and DEMQoL-U for demen-
tia [10]. Thirdly, the preferences of the patient population
towards their own current health may be measured
directly, typically also using VAS, SG or TTO.
Reimbursement agencies, such as the National Insti-
tute for Health and Care Excellence (NICE) in England,
now routinely assess the cost effectiveness of new health
care interventions. This has resulted in a corresponding
increase in the demand for data on HSUVs to populate
effectiveness models. In the case of visual conditions,
models are usually built around a set of health states de-
fined by visual acuity (VA). The NICE reference case, for
example, specifies that HSUVs should be derived from
standardised and validated generic instruments which
use a choice-based method (either TTO or SG) and
should involve preferences from the general public
[11]. A further recommendation specifies a preference
for EQ-5D values and this has additional importance
in the UK context.
Conditions such as diabetic retinopathy (DR), diabetic
macular oedema (DMO) and age-related macular degen-
eration (AMD) have important implications for HRQoL.
The changes in HSUVs as a patient moves between dif-
ferent VA levels are important parameters in modelling
the effects of interventions that influence or modify the
disease process for these conditions. Earlier reviews of
utilities have focused on peripheral or central visual loss
[12], the impact of eye complications in diabetic patients
[13] and the psychometric properties of specific meas-
urement tools [14].
The aim of this review was to assess the impact of VA,
in the better-seeing eye (BSE) and worse-seeing eye
(WSE) on HSUVs in patients with DR, DMO or AMD.
Methods
Literature searching
Initial searches were conducted in February 2012 in MED-
LINE (Ovid MEDLINE (R) In-Process & Other Non-
Indexed Citations and Ovid MEDLINE (R) 1946 to January
Week 4 2012) in February 2012. Major electronic databases
searched included the Cochrane Library (Issue 3); EMBASE
(1980 Week 40 2009); Econlit (1969 to September 2009);
CINAHL (1994 to September 2009) and Web of Science.
Supplementary database searches for on-going or unpub-
lished research were undertaken within the web-pages of
the National Research Register Archive, Turning Research
into Practice (TRIP) and Index to theses. Reference lists of
identified reviews were also examined for relevant articles.Both controlled and free text terms were used. Free
text terms included “visual acuity”, “preference score”,
“euroqol”, “time trade off” and “standard gamble”. While
condition-specific terms were applied to searches in the
major databases, such terms and their synonyms were
combined with HSUV terms for supplementary searches.
An example of the search strategy used in the MEDLINE
is shown in Additional file 1.
Study selection
Studies were included if HSUVs were elicited using dir-
ect methods (such as TTO and SG) or preference-based
instruments (for example EQ-5D, HUI3 and SF-6D) in
relevant populations with reported VA levels. Only full
text publications in English were included; there were
no other restrictions. Studies that reported utilities based
on scenarios or vignettes were excluded. This review is
about the association between VA and HSUVs, and
while vignettes may be intended to reflect the conse-
quences of different levels of VA, there is no measure-
ment of VA.
Data extraction and quality assessment
Study selection, data extraction and quality assessment
was undertaken by EP and checked for accuracy and
completeness by JC or JB. Disagreements were resolved
through discussion. A piloted standardised form was
used for data extraction. Information abstracted included
study characteristics (country of study, study design, in-
clusion criteria), characteristics of respondents (age, gen-
der, mean visual acuity at baseline, if provided), methods
of utility elicitation, mean HSUVs and HSUVs for defined
VA levels. Where available, information on regression
models and coefficients of regressions were extracted.
To date, there is no consensus on recommended cri-
teria for undertaking quality assessment of health state
utility values [15]. Therefore, we assessed quality in
terms of the recruitment and selection of the patients
together with completion rates of the utility measures in
order to assess the representativeness of the sample of
the patient group and this information was used in the
narrative review.
Data synthesis and analysis
Due to expected variations in reported VA, a priori clas-
sification of VA in 4 groups based on levels reported by
Brown et al. [16] was adopted to facilitate comparison of
HSUVs across studies. The ‘Brown’ classification [16]
presented in Table 1 was adopted because it was the
most widely used in the available literature. Reported VA
levels were converted to Snellen units (20 feet), when re-
quired, using a conversion scale described by the Inter-
national Council of Ophthalmology [17,18]. Weighted
means of reported utilities of specified VA groups were
Table 1 Visual levels according to Brown 2002 [16]
Description of vision Visual acuity
Good reading vision 20/20 – 20/25
Legal driving vision 20/30 – 20/40
Moderate visual loss 20/50 – 20/100
Legal blindness ≤ 20/200
This table displays the reported visual acuity classes by Brown et al. [16]. This
classification was used because it was the most widely reported in the
available literature and also provided meaningful interpretation of
visual impairment.
Number of duplicates
94
Number of potentially relevant 
records
384
Number of full-text  
articles excluded
33
Number of citations screened
290
Number of full-text articles 
examined for eligibility
55
Number of full-text articles 
included the review
22
Related to 17 studies
Number of citations  
exclude at title/abstract 
stage
235
Figure 1 Flow diagram of study selection. Figure 1 is a flow
diagram study selection based on pre-specified eligibility criteria.
A total of 384 potentially relevant papers were identified. After
de-duplication, 290 citations were screened based on their titles
and available abstracts. Following the exclusion of 235 citations,
55 full text papers were retrieved for detailed examination. A total
of 22 papers (relating to 17 studies) matched the eligibility criteria. Of
these, one unique study involved the simulation of visual acuity levels
of AMD in members of the general public. Studies that assessed ocular
patients with an unspecified DR or AMD population provided
information related to vision in the worse-seeing eye but were
less useful for examining the relationship between HSUVs and vision.
In all, 9 studies had data that could be used in the analysis of the
impact of visual acuity on elicited preferences.
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tween individual VA groups, the pooled variance was
calculated using the formula [18]:
s2p ¼
Xk
i
¼ 1 ni−1ð Þs2i
 
Xk
i
¼ 1 ni−1ð Þ
where sp
2 = pooled variance; ni = sample size of the ith
sample; si
2 = variance of the ith sample; k = number of
samples being combined; (n – 1) was used to give an un-
biased estimate of the pooled variance of the mean, as-
suming an equal population variance.
Re-classification of VA levels was not possible for all
studies. Furthermore, this was not adopted in studies
reporting HSUVs by VA in the WSE. For these studies,
the VA groups used in the published paper were main-
tained. The extent of heterogeneity in study designs and
populations made it inappropriate to perform a formal
meta-analysis.
Results
A flow diagram of the study selection is shown in Figure 1.
Of 384 potentially relevant records, 22 full-text articles re-
lating to 17 studies were included in this review.
Description of included studies
No relevant study was identified for DMO patients. Over-
all, there were two strands of studies; studies reporting
HSUVs according to VA levels in a specified population of
DR or AMD patients (or a combination) [16,19-29] and
studies with VA levels provided for an entire study popula-
tion with ocular conditions which included patients with
relevant conditions (i.e. where VA were not split by condi-
tion) [30-34]. The second group of studies provided useful
information related to VA in the WSE. Of the 17 relevant
studies, 9 studies [16,19,23,24,27,30,32-34] had VA data
that could be re-classified into the ‘Brown’ VA groups
[16]. Characteristics of the study populations and methods
of VA and HSUV assessments including age, gender, utility
elicitation instruments, mean VA and HSUV for study
participants at baseline are presented in Table 2.
In the absence of a consensus relating to quality as-
sessment of health utility studies, representativeness ofstudy population was considered as a key feature [14]. A
descriptive summary of quality assessment is presented
in Additional file 2. Patient recruitment resulted in a
relevant selection of patients in all but one study [21]
that included a sample from the general UK population.
While most studies provided sufficient information on
the type of visual condition (e.g. AMD or DR) consid-
ered, there was a general lack of detail to confirm the
ophthalmic diagnosis or the presence of associated visual
co-morbidities. The proportion of the study population
that completed utility elicitation was indicative of the re-
sponse rate in each study. Whereas a response rate of
46% (n = 209/451) was reported in one study of AMD
patients, [22] on average, response rate across remaining
studies was 97%. However, these response rates are hard to
interpret due to insufficient or missing information on
withdrawals, drop-outs or non-responders [19,26,28]. Over-
all, study quality based on sample representativeness and
response rate, was considered to be satisfactory for studies
Table 2 Summary of included studies
STUDY REFERENCE, CONDITION,
(NUMBER OF PATIENTS)
COUNTRY MEAN AGE,
YEARS (SD)
FEMALES (%) REFERENCE EYE (UNITS
OF VA MEASUREMENT)
MEAN VA AT
BASELINE (S )
HEALTH STATE UTILITY
MEASURE (ANCHOR)
MEAN UTILITY
AT BASELINE
Aspinall et al. [19] UK 77.8 42 Binocular (distant) vision 0.49 TTO (perfect vision) 0.81
(6.7) (0.43)
AMD (122) Binocular (near) vision
(logMAR)
0.72
(0.43)
Au Eong et al. [20] Singapore 68.1 62 BSE NR EQ-5Da 0.89
(9.4)
WSE NR TTO (perfect vision) 0.81
AMD (338) WVA (logMAR) NR SG (perfect vision/death) 0.86
SG (perfect vision/binocular
blindness)
0.91
Brown [30] USA 67.5 63 BSE NR TTO (perfect vision) NR
DR (107) WSE (Snellen units, feet) NR SG (perfect health/death) NR
AMD (107)
Macular
Oedema (5)
Brown et al. [31]a,b USA WSEc (Snellen units, feet) TTO (perfect vision) NR
DR (28) [Unilateral good vision group] 66 59 0.33 to 1.0
AMD (36) (11)
Macular
Oedema (2)
[Bilateral good vision group] 60 58 0.8 to 1.0
(10)
Brown et al. [16] USA BSE (Snellen units, feet) TTO (perfect vision) 0.74
DR (333) DR 62.2 58 20/40
AMD (248) (11.8)
AMD 73.2 43 20/45
(9.8)
Brown et al. [32]a USA 67.5 61 BSE (Snellen units, feet) NR TTO (perfect vision) 0.79
(12.2)
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Table 2 Summary of included studies (Continued)
DR (170)
AMD (145)
Czoski-Murray et al. [21]c UK 32.0 51 BSE NR TTO (full health) NR
(12.5)
AMD (108)
Espallargues et al. [22] UK 79.6 58 BSE 1.01 EQ-5D 0.72
(7.5) (0.67)
AMD (209) WSE 1.68 HUI-3 0.34
(0.75)
Binocular (distant) vision 0.49 SF-6D 0.66
(0.43)
Binocular (near) vision (logMAR) 0.46 TTO (full health) 0.64
(0.88)
Lee et al. [23]d USA 75.4 50 BSE (Snellen units, feet)f 0.4 SG (perfect vision/death) 0.83-0.87
(6.2) (0.41)
DR (58) SG (perfect vision/unilateral
blindness)
0.66-0.79
AMD (44)
Lloyd et al. [24] UK NR NR BSE (Snellen units, metres) NR EQ-5D NR
DR (122)
Reeves et al. [25] UK NR NR BSE (ETDRS letters) NR SF-6D NR
AMD (1,829)
Sahel et al. [26] France, Germany, Italy 77 60 BSE 0.49 HUI3 0.48
(8.0)
AMD (360) WSE (logMAR) 1
Shah et al. [33]a USA 67.5 66 BSE (Snellen units, feet) NR TTO (perfect vision) NR
DR/AMD(150)
Sharma et al. [34]a Canada 67.5 64 BSE (Snellen units, metres) NR TTO (perfect vision) 0.78
(11.9)
DR (105) SG (perfect vision/death) 0.85
AMD (107)
Sharma et al. [27] Canada 63.5 48 BSE (Snellen units, metres) NR TTO (perfect vision) NR
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(12.5)
DR (221)
Soubrane et al. [28]e Canada, France, Germany,
Spain, UK
78.1 65 BSE (Snellen units, feet)f 0.6 EQ-5D 0.65
(6.9) (0.7)
AMD (401)
Yanagi et al. [29] Japan 75.9 85 BSE (logMAR) NR TTO (perfect vision) 0.6
AMD (48) SG (perfect vision/death) 0.7
Abbreviations: BGV bilateral good vision, BSE better-seeing eye, EQ-5D EuroQol, HUI3 Health Utilities Index Mark 3, logMAR logarithm of the minimum angle of resolution, NR not reported, SF-6D Short Form 6D, TTO time
trade-off, SG standard gamble, UGV unilateral good vision, WSE worse-seeing eye, WVA weighted visual acuity.
aThe study participants had different ocular conditions including DR, macular oedema (undefined) and AMD. Sample sizes presented here are based on the proportion of patients with DR, AMD or macular oedema
within the study population.
bThis study compared utilities between patients with bilateral (n = 69) and unilateral good vision (n = 81).
cIn this study, AMD health states were simulated by using contact lenses in a healthy sample of a general population.
dOver 50% of patients had mild DR, while only 2 out of 10 AMD patients had moderate disease.
eThis study compared utilities in patients with AMD and non-AMD ‘controls’.
fSnellen units were converted to logMAR units.
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HSUVs [16,19,23,24,27,30,32-34] (see Additional file 2).
Visual acuity and health utility state values
Reporting of VA levels varied across studies. Visual im-
pairment was based on VA in better-seeing eye (BSE)
[16,20-24,27-34], worse-seeing eye (WSE) [20,22,26,30,31],
binocular distance visual acuity [19,22] and weighted vis-
ual acuity (WVA) [20] defined as weighted average of VA
in both eyes. HSUVs reported in included studies were
EQ-5D, [20,22,24,28] SF-6D, [22,25] HUI-3, [22,24,26]
TTO [16,20-22,27,29-34] and SG [20,23,29,30].
Overall, generic EQ-5D estimates were found to be
largely unresponsive to differences in VA levels [22]. By
contrast, TTO estimates generally displayed a more con-
sistent reduction across VA levels. However, SG-based
utility estimates tended to be higher than TTO estimates
in the same patients and these in turn were higher than
the values from generic instruments. Furthermore, shifts
in utility estimates across VA levels did not always ex-
hibit a definitive pattern across consecutive levels of
visual impairment.
Reported HSUVs according to VA in the BSE are shown
in Table 3. In DR patients, TTO estimates decreased with
worsening VA in the BSE; [16,19,23,24,27,30,32-34] with
the greatest reduction occurring between moderate visual
loss (20/50 to 20/100) and legal blindness (≤ 20/200). EQ-
5D and HUI3 (mean ± SD) estimates for good reading vi-
sion to VA corresponding to counting fingers or worse
ranged from ranged from 0.75 ± 0.23 to 0.34 ± 0.36 and
0.78 ± 0.22 to 0.37 ± 0.00, respectively [24]. The observed
greater disutility in patients with worsening vision was ex-
plained by an anticipated or greater dependence on others
[24]. Alternatively, this pattern may also have resulted
from the small sample sizes of patients (n < 20 for all
groups below good reading vision).
Patients with AMD showed a monotonic reduction in
TTO estimates with decreasing VA [22] and [21], al-
though these VA levels could not be re-classified using
the ‘Brown’ groups. TTO estimates in patients with
good reading vision in the study reported by Espallargues
et al. [22] were lower compared to those reported by
Brown et al. [16] and Aspinall et al. [19]. However, further
comparisons of Brown et al., [16] and Aspinall et al., [19]
with Espallargues (2005) [22] and Czoski-Murray et al.
[21] are limited by differences in VA stratifications and
elicitation methods (see Additional file 3). Nonetheless,
there were comparable reductions in mean TTO utilities
in the BSE in all 3 studies [16,19,22]. The lowest TTO es-
timate for good reading and the largest decline across the
VA groups was observed in a population with simulated
AMD states and this was probably because the values
were provided by the general population who might not
be able to adapt in the study [21].Some studies used perfect vision as the upper anchor,
but for policy purposes it is important to use perfect or
full health as the upper anchor. The choice of the upper
anchor is important since it has been shown to impact
on estimated utilities. SG estimates based on the policy
scale (perfect health/death) and the vision scale (perfect
vision/unilateral blindness) [23] showed comparable uti-
lities for mild to moderate visual loss (0.86 ± 0.24 to 0.89 ±
0.23) but contrastingly different estimates for patients with
profound visual disability (0.39 ± 0.37 to 0.76 ± 0.30). This
suggests that patients with severe visual impairment may
be more willing to accept the risk of unilateral blindness
compared to dying. As such, it is important to note the
effect of different anchors in HSUVs elicitation, and how
this may influence results of relevant cost-utility analyses.
Better-seeing eye and worse-seeing eye
Available data [20,22,26,30,31] on the impact of vision
on HSUVs in the BSE and WSE indicated that for VA
levels of 20/200-20/400 to no perception of light in the
WSE, TTO estimates ranged from 0.94 ± 0.13 to 0.81 ±
0.16 [31]. Brown et al., [35] reported elsewhere that cor-
relation coefficients (Spearman rank co-efficient) for
TTO values and SG values for VA in the BSE and WSE
were 0.46 (p < 0.001) and 0.37 (p < 0.001), whereas co-
efficients of 0.27 (p < 0.001) and 0.25 (p < 0.001) were re-
ported in relation to VA in the WSE. Sahel et al. [26]
reported a likely relationship between vision in BSE (p <
0.01) or vision in WSE (p = 0.7) and HUI-3 scores. Add-
itionally, a study of AMD patients in Singapore [20]
reported a weak correlation between EQ-5D estimates
and weighted visual acuity (WVA) (defined as weighted
average of VA in both eyes), VA in the BSE and VA in
the WSE (Pearson’s correlation coefficient, -0.305, -0.91
and -0.27 respectively). TTO values were also weakly asso-
ciated with WVA (Pearson’s coefficient, -0.228) and VA in
the WSE (Pearson’s coefficient, -0.237). Conversely for SG
estimates based on a ‘policy’ scale (perfect vision/death)
and a ‘modified’ scale (perfect vision/binocular blindness),
the authors reported no association with WVA or VA in
the BSE and WSE.
Reported regression analyses conducted with VA as a
dependent variable demonstrated a significant relation-
ship between VA in the BSE and reported TTO values
(P < 0.0001 to 0.01) [30-32,34] which was absent for vi-
sion in the WSE (p =0.43) [32]. Sharma et al. [34] also
identified VA in the affected eye (p < 0.01) and VA in the
normal eye (p < 0.01) as significant predictors of utility.
Using a mixed regression model, Reeves et al. [25] pre-
dicted changes of SF-6D values by 0.0058 and 0.116 for
5-letter and 100-letter decreases in BVCA. BCVA in the
BSE, however, remained a strong predictor of SF-6D mea-
sures (p < 0.0001). Table 4 shows a summary of results of
various regression analyses reported in the literature.
Table 3 Utility estimates according to visual acuity in the better-seeing eye
STUDY REFERENCE HSUV
INSTRUMENT
MEAN
UTILITY
(SD)
VISUAL ACUITY
20/20 TO 20/25 20/30 TO 20/40 20/50 TO 20/100 ≤ 20/200
MEAN (SD) MEAN (SD) MEAN (SD) MEAN (SD)
N N N N
STUDIES WITH VISUAL ACUITY LEVELS BASED ON
RELEVANT CONDITIONS
DR STUDIES
Lloyd et al. [24] EQ-5D NR 0.75(0.23) 0.50(0.30) 0.68(0.29) 0.53(0.47)
68 13 10 7
0.34(0.36)a
3
Lloyd et al. [24] HUI3 NR 0.78(0.22) 0.30(0.38) 0.61(0.35) 0.52(0.50)
68 13 10 7
0.37(0.00)a
3
Brown et al. [16] TTO 0.79 0.86(0.17) 0.80(0.19) 0.77(0.18) 0.61(0.19)
(0.2) 72 130 95 36
Sharma et al. [27] 0.79 0.88(0.19) 0.79(0.22) 0.73(0.26) 0.73(0.22)
(0.2) NR NR NR NR
0.48(0.47)a
NR
AMD STUDIES
Aspinall et al. [19]c TTO 0.81 0.93 0.86 0.74 0.68
0.76b
Brown et al. [16] 0.74(0.23) 0.84(0.21) 0.80(0.19) 0.71(0.22) 0.59(0.22)
60 65 57 65
Lee et al. [23] SGd 0.89(0.23) 0.76(0.30) NR NR
23 21
Lee et al. [23] SGe 0.86(0.24) 0.39(0.37) NR NR
23 21
STUDIES WITH VISUAL ACUITY LEVELS NOT
BASED ON RELEVANT CONDITIONSf
Brown [30] TTO 0.89(0.17) 0.82(0.21) 0.74(0.21) 0.62(0.20)
82 98 89 38
0.46 (0.29)a
18
Brown et al. [32] 0.88(0.15) 0.81(0.21) 0.72(0.21) 0.61(0.19)
127 218 83 72
Shah et al. [33] 0.88(0.19) 0.90(0.14) 0.76(0.23)
71 43 22
Sharma et al. [34] 0.91(0.15) 0.80(0.21) 0.71(0.21) 0.62(0.20)
75 136 58 37
0.473(0.32)
17a
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Table 3 Utility estimates according to visual acuity in the better-seeing eye (Continued)
Brown [30] SG 0.94 (0.12) 0.90(0.19) 0.81(0.21) 0.74(0.21)
82 98 89 38
0.60(0.30)
18a
Sharma et al. [34] 0.95(0.11) 0.90(0.17) 0.77(0.28) 0.74(0.22)
75 136 58 37
0.60(0.32)
17a
Abbreviations: AMD age-related macular degeneration, DR diabetic retinopathy, EQ-5D EuroQol values, HUI3 Health utilities index Mark 3 values, NR not reported,
SD standard deviation, SG standard gamble values, TTO time-trade-off estimates.
aValues for levels corresponding to counting fingers to no light perception.
bValues for levels corresponding to counting fingers to light perception.
cVA level based on binocular distance vision and not VA in the better seeing-eye. Authors stated that the difference between the two measures was not signifi-
cant. SD not calculated because of missing data. Figures shown were derived from the nearest equivalent Snellen categories of VA in the relevant article.
dStandard gamble values based on the policy scale; anchors used were perfect vision/death.
eStandard gamble values based on the vision scale; anchors used were perfect vision/unilateral blindness.
fRelevant populations refers to patients with diabetic retinopathy and age-related macular degeneration. Macular oedema was not described in full, so it is unclear
if patients had diabetic macular oedema.
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This review showed a general decline in HSUVs as VA
deteriorates in the BSE in AMD and DR but the rela-
tionship between VA and HSUVs was weak or absent in
the WSE. This finding was not consistent across studies
and this could be partly explained by the heterogeneity
of included studies. No relevant studies were identified
for a specified population of DMO patients. Methodo-
logical diversity was partly overcome by using a common
classification used by Brown et al. [16]. However, this
did not work in all cases and additionally has not been
validated as the most clinically relevant classification. Al-
though, regression models of HSUVs to VA were identi-
fied, models were not specified in the same way and
little is known about the performance of the models.
However, publication of regression models is most help-
ful as it allows the extrapolation of results to situations
where the VA classification needs to be different.
Regarding anchors for utility elicitation, a majority of
TTO and SG studies used perfect vision as the upper
anchor rather than perfect health which suggests in a
narrower scale resulting in lower scores and ranges for
improvement. For economic evaluation, perfect or full
generic health is recommended to enable cross programme
comparison [36]. In this review, self-reported TTO and SG
estimates showed a monotonic relationship to VA espe-
cially in the BSE (with one or two exceptions); the generic
EQ-5D and SF-6D preference-based measures tended to
lack responsiveness to changes in VA, specifically in AMD
patients. Whereas SG estimates tended to be higher than
TTO values in the same patients and these in turn were
higher than the values from the generic instruments, the
anchor points were not always the same (perfect vision ver-
sus full health). Therefore, it was difficult to compare these
estimates. Furthermore, the non-responsiveness of the EQ-5D in visual conditions has been observed in previous re-
views and this phenomenon has been explained by the lack
of a vision-specific dimension [13,14]. One important de-
velopment to overcome this limitation, is to identify
condition-specific dimensions (bolt-on items or dimension
extensions) to improve the usefulness of the EQ-5D in
vision-related conditions [37,38]. An alternative approach
would be to obtain data from patients using a preference-
based version of a disease-specific instrument and one has
recently become available based on the National Eye Insti-
tute Vision Function Questionnaire (NEI-VFQ 25) [39]
Field test results indicate that the NEI-VFQ 25 is a reliable
and valid instrument in comparing vision-related HRQoL
across groups of patients [40,41]. Furthermore, a number
of clinical and epidemiological studies have supported its
validity in patients with AMD [40,42] and other chronic
eye disorders [43-45].
An interesting finding from the literature review was
the limited evidence on the relationship between HSUVs
and VA in the WSE. This has important implications for
the cost effectiveness modelling since clinical practice is
concerned with treating the person and not just an indi-
vidual eye. It would seem that having problems in the
weaker eye has little or no impact on HSUVs after con-
trolling for VA in the BSE in patients with AMD or DR.
However there are significant limitations in the literature
regarding the relationship between VA in the WSE or
overall VA and HSUVs and this require significant work
for the future.
This review is important because it provides estimates of
HSUVs for defined VA levels. It also reports regression co-
efficients which in turn provide information on the rela-
tionship between VA and HSUVs. AlthoughVA levels were
re-classified, this was not possible for all studies. Small
samples sizes of included studies introduced a significant
Table 4 Summary of reported multiple regression analyses in included studies
STUDY TYPE OF
REGRESSION
MODEL
RESULTS OF ANALYSIS NOTES
DEPENDENT
VARIABLE
Β-COEFFICIENT P-VALUE
(SE)
PREDICTORS OF TTO
VALUES
Brown et al. [30] OLS regression VA (Snellen) in BSE 0.37 <0.0001 The following equation was developed
from the model:
Utility value = 0.37 (VA) + 0.514,
Brown et al. [31] OLS regression VA (Snellen), 1
‘good’ eye
−0.0902 0.001 Significant differences in reported utility
values were noted when patients with
two ‘good’ eyes (bilateral good vision)
were compared with those with one
‘good’ eye (unilateral good vision).
Brown et al. [32] OLS stepwise model VA (Snellen), BSE NR <0.0001 A significant relationship was demonstrated
between decreasing vision in the BSE and
decrements in utility values. This relationship
was absent for VA in the WSE.
VA (Snellen), WSE NR 0.43
Espallargues et al. [22] OLS Stepwise model Distant VA (logMAR),
BSE
−0.04 0.686 An association was observed between
distant VA in the BSE and TTO scores.
Selection criteria for significant predictors
were p < 0.1. Age and time since diagnosis
were important for TTO values.
(0.05)
Sharma et al. [34] OLS model VA (logMAR), BSE 0.176 <0. 01 VA levels in both the affected eye (p < 0.01)
and unaffected eye (p < 0.01) were independently
associated with reported utilities. Better vision
was associated with higher scores.
PREDICTORS OF SG
VALUES
Lloyd et al. [24] Mixed model analysis VA (Snellen), BSE NR NR The VA levels were based on the levels of
vision used in the health state cards developed
for the study. The authors reported that
described states were significant in predicting
utility. Further analysis showed that SG values
were not associated with a patient’s visual
acuity level.
Sharma et al. [34] Bivariate analysis VA (logMAR), BSE 0.193 <0. 01 VA levels in both the affected eye (p < 0.01)
and unaffected eye (p < 0.01) were independently
associated with reported utilities. Better vision
was associated with higher scores.
Multivariate analyses
PREDICTORS OF HUI-3
VALUES (GLOBAL)
Espallargues et al. [22] Multiple linear regression Distant VA (logMAR),
BSE
−0.12 0.226 A selection criterion of p < 0.1 was adopted
for a backward stepwise regression model
of relevant variables. Significant variables
were contrast sensitivity, illness (es) of long
duration and age.
(0.43)
Univariate regression VA (logMAR), BSE −0.14 <0.01
(0.03)
Sahel et al. [26] Multiple regression BSE: WSE NR NR The adjusted R-squared showed that 21%
of the variance in the global score was
due to the VA levels [p < 0.01 (BSE);
p = 0.31(WSE)].
≥20/40: ≥ 20/200 0.6 NR
≥20/40: < 20/200 0.57 NR
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Table 4 Summary of reported multiple regression analyses in included studies (Continued)
<20/40: ≥ 20/200 0.41 NR
< 20/40: <20/200 0.42 NR
PREDICTORS OF HUI-3
VALUES (VISION
DIMENSION)
Espallargues et al. [22] Univariate regression VA (logMAR), BSE −0.25 <0.01
(0.26)
Multivariate analyses VA (logMAR), BSE −0.21 <0.01
(0.04)
Sahel et al. [26] Multiple regression BSE: WSE Authors reported that 36% of the variance
in the visual dimension of the HUI-3 score
was expressed by the adjusted R-squared
value [p < 0.01 (BSE); p = 0.7(WSE)].
≥20/40: ≥ 20/200 0.75 NR
≥20/40: < 20/200 0.74 NR
<20/40: ≥ 20/200 0.42 NR
< 20/40: <20/200 0.37 NR
Abbreviations: BSE better-seeing eye, EQ-5D euroQol values, HUI-3 health utilities index mark3, logMAR logarithm of minimum angle of resolution, NR not reported, OLS ordinary
least square, SE standard error, SG standard gamble values, TTO time-trade-off values, VA visual acuity,WSE worse-seeing eye.
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analysis. Statistical pooling of results was also inappropriate
due to heterogeneity of relevant studies. More HSUVs
measures need to be used in clinical studies in order to
provide better evidence for economic evaluation.Conclusions
The current review presents a comprehensive overview
of HSUVs in AMD and DR by VA levels reflecting a
range of visual abilities. No relevant studies were identi-
fied for patients with DMO. Vision loss tends to have an
obvious impact on patients’ quality of life, especially in
the BSE, as shown in most of the literature. However,
the relationship between VA and HSUVs is not the same
between conditions or affected eyes, and is strongly re-
lated to the instrument and utility elicitation method-
ology used for HSUV elicitation. Most studies are
concerned with VA in the BSE, but this is not always
relevant for policy makers. There is very limited evi-
dence in the WSE by VA categories.
In terms of instruments, the widely used EQ-5D does
not reflect the problems associated with chronic eye
conditions like AMD and DR, whereas HUI3, TTO and
SG showed comparatively stronger associations with VA
in the BSE. The use of a vision-specific instrument such
as one based on the NEI-VFQ 25 may be a more appro-
priate measure of self-reported HRQoL in patients with
visual disability. The QALY gains estimated in this way
may better reflect the impact of the clinical intervention
and the benefit observed by patients.Additional files
Additional file 1: Search strategy used in MEDLINE (Ovid).
This shows a search strategy of a combination of free text words and
MESH terms used to search the MEDLINE database (Ovid MEDLINE (R)
In-Process & Other Non-Indexed Citations and Ovid MEDLINE (R) 1946 to
January Week 4 2012).
Additional file 2: Quality assessment of included studies. This is a
descriptive summary of quality assessment of included studies in the
review. Quality assessment of included studies focused on the
recruitment and selection of the patients together with completion rates
in order to assess the representativeness of the sample of the patient
group. Additional items considered were response rate to utility
elicitation methods of utility elicitation as well as identifying potential
confounding variables.
Additional file 3: Table showing utilities reported by Czoski-Murray
et al., 2009 [21] and Espallargues et al., 2005 [22]. This table displays
vision-related estimates from two studies relating to age-related macular
degeneration (AMD). Reported visual levels used in these studies could
not be adapted using the pre-specified levels used in the study by Brown
et al. [16]. Furthermore, contact lenses were used to simulated AMD
visual health states in a healthy population in the study by Czoski-Murray
et al., 2009 [21] while the study by Espallargues et al., 2005 [22] obtained
estimates from patients with the condition.
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